{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:36:12Z","timestamp":1789691772177,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In patients with frequently relapsing nephrotic syndrome, immunosuppressive therapy such as cyclosporine are often required to maintain remission. Cyclosporine has been noted to have tumorgenesis effects. In this case report, we present a child with relapsing nephrotic syndrom developed a rhabdomyosarcoma on her tongue after adout 4 years of continual immunosuppressive therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 2-year-old female child had nephrotic syndrome (urine protein-creatinine ratio 749.1\u2009mg\/mg; blood urea nitrogen 11\u2009mg\/dL; serum creatinine 0.3\u2009mg\/dL; and serum albumin 1.8\u2009g\/dL.) Proteinuria resolved on treatment with daily prednisolone for 4 weeks at the dose of 45\u2009mg (2.5\u2009mg\/kg\/day) but recurred with taper from 25\u2009mg\/day to 10\u2009mg\/day. At least five more episodes of relapse occurred within about a 3-year period. After the third relapse, she was treated with prednisolone and cyclosporine (at initial dose of 50\u2009mg\/day [1.7\u2009mg\/kg\/day]) for immunosuppression. About 4 years after the diagnosis of nephrotic syndrome had been made, an embryonal rhabdomyosarcoma developed on her tongue. The cancer was treated with TPOG-RMS-LR protocol, with vincristine, actinomycin, and cyclophosphamide. Magnetic resonance imaging scan, performed about 3 years after the start of TPOG-RMS-LR therapy, revealed complete remission of the cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Although treatment with cyclosporine cannot be conclusively implicated as the cause the rhabdomyosarcoma in this patient, the association should prompt consideration of its use in the treatment of frequently relapsing nephrotic syndrome in children.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-02136-6","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:20:42Z","timestamp":1605615642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rhabdomyosarcoma in a child with nephrotic syndrome treated with cyclosporine: a case report with literature review"],"prefix":"10.1186","volume":"21","author":[{"given":"Huai-Chueh Gem","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Neng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Shiuh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5279-0660","authenticated-orcid":false,"given":"Yuan-Yow","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"issue":"4","key":"2136_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/20469047.2017.1374003","volume":"37","author":"ML Downie","year":"2017","unstructured":"Downie ML, Gallibois C, Parekh RS, Noone DG. Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health. 2017;37(4):248\u201358.","journal-title":"Paediatr Int Child Health"},{"issue":"10141","key":"2136_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61\u201374.","journal-title":"Lancet"},{"key":"2136_CR3","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00467-020-04570-y","volume":"35","author":"JA Kari","year":"2020","unstructured":"Kari JA, Alhasan KA, Albanna AS, Safdar OY, Shalaby MA, Bockenhauer D, El-Desoky SM. Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2020;35:1445.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2136_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/pbc.24118","volume":"59","author":"S Malempati","year":"2012","unstructured":"Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59(1):5\u201310.","journal-title":"Pediatr Blood Cancer"},{"issue":"1 Pt 2","key":"2136_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jfma.2018.05.015","volume":"118","author":"SW Chou","year":"2019","unstructured":"Chou SW, Chang HH, Lu MY, Yang YL, Lin DT, Lin KH, Jou ST. Clinical outcomes of pediatric patients with newly diagnosed rhabdomyosarcoma treated by two consecutive protocols - a single institution report in Taiwan. J Formos Med Assoc. 2019;118(1 Pt 2):332\u201340.","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"2136_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.mehy.2004.03.030","volume":"63","author":"N Andre","year":"2004","unstructured":"Andre N, Roquelaure B, Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses. 2004;63(4):647\u201352.","journal-title":"Med Hypotheses"},{"issue":"7","key":"2136_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/mc.20744","volume":"50","author":"SB Walsh","year":"2011","unstructured":"Walsh SB, Xu J, Xu H, Kurundkar AR, Maheshwari A, Grizzle WE, Timares L, Huang CC, Kopelovich L, Elmets CA, et al. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFbeta signaling pathway. Mol Carcinog. 2011;50(7):516\u201327.","journal-title":"Mol Carcinog"},{"issue":"2","key":"2136_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10157-007-0015-4","volume":"12","author":"WA Olowu","year":"2008","unstructured":"Olowu WA, Salako AA, Adelusola KA, Sowande OA, Adetiloye VA, Adefehinti O, Osasan SA. Focal segmental glomerulosclerosis and nephrotic syndrome in a child with embryonal rhabdomyosarcoma. Clin Exp Nephrol. 2008;12(2):144\u20138.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"2136_CR9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00467-017-3641-4","volume":"32","author":"Y Hamasaki","year":"2017","unstructured":"Hamasaki Y, Komaki F, Ishikura K, Hamada R, Sakai T, Hataya H, Ogata K, Ando T, Honda M. Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment. Pediatr Nephrol. 2017;32(8):1383\u201390.","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"2136_CR10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ki.2008.24","volume":"73","author":"K Ishikura","year":"2008","unstructured":"Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Honda M. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73(10):1167\u201373.","journal-title":"Kidney Int"},{"issue":"6","key":"2136_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1432-2277.2003.tb00327.x","volume":"16","author":"M Cescon","year":"2003","unstructured":"Cescon M, Grazi GL, Assietti R, Scanni A, Frigerio F, Sparacio F, Ercolani G, Cavallari A. Embryonal rhabdomyosarcoma of the orbit in a liver transplant recipient. Transpl Int. 2003;16(6):437\u201340.","journal-title":"Transpl Int"},{"issue":"10","key":"2136_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s004170050162","volume":"236","author":"M Muramatsu","year":"1998","unstructured":"Muramatsu M, Kotake S, Yoshikawa K, Sasamoto Y, Matsuda H, Yamawaki S. The development of malignant rhabdoid tumor in a patient with Behcet's disease treated with ciclosporin. Graefes Arch Clin Exp Ophthalmol. 1998;236(10):798\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2136_CR13","first-page":"38","volume":"108","author":"P Piller","year":"1991","unstructured":"Piller P, Herman D, Stierle JL, Conraux C. Rhabdomyosarcoma of the nasopharynx occurring with immunosuppressive treatment with cyclosporin a. apropos of a case. Ann Otolaryngol Chir Cervicofac. 1991;108(1):38\u201340.","journal-title":"Ann Otolaryngol Chir Cervicofac"},{"key":"2136_CR14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fimmu.2019.00588","volume":"10","author":"C Flores","year":"2019","unstructured":"Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O. Lessons to learn from low-dose Cyclosporin-a: a new approach for unexpected clinical applications. Front Immunol. 2019;10:588.","journal-title":"Front Immunol"},{"key":"2136_CR15","doi-asserted-by":"crossref","unstructured":"Majd N, Sumita K, Yoshino H, Chen D, Terakawa J, Daikoku T, Kofuji S, Curry R, Wise-Draper TM, Warnick RE, et al. A review of the potential utility of mycophenolate mofetil as a cancer therapeutic. J Cancer Res. 2014:423401.","DOI":"10.1155\/2014\/423401"},{"issue":"1","key":"2136_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5152\/eurasianjmed.2018.18194","volume":"51","author":"M Simsek","year":"2019","unstructured":"Simsek M, Tekin SB, Bilici M. Immunological agents used in Cancer treatment. Eurasian J Med. 2019;51(1):90\u20134.","journal-title":"Eurasian J Med"},{"issue":"6","key":"2136_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/01.TP.0000173770.42403.F7","volume":"80","author":"BD Kahan","year":"2005","unstructured":"Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, Van Buren CT. Low incidence of malignancy among sirolimus\/cyclosporine-treated renal transplant recipients. Transplantation. 2005;80(6):749\u201358.","journal-title":"Transplantation"},{"issue":"6719","key":"2136_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/17401","volume":"397","author":"M Hojo","year":"1999","unstructured":"Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530\u20134.","journal-title":"Nature"},{"issue":"10","key":"2136_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1600-0625.2011.01320.x","volume":"20","author":"C Kuschal","year":"2011","unstructured":"Kuschal C, Thoms KM, Boeckmann L, Laspe P, Apel A, Schon MP, Emmert S. Cyclosporin a inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group a and G proteins, which is mediated by calcineurin inhibition. Exp Dermatol. 2011;20(10):795\u20139.","journal-title":"Exp Dermatol"},{"issue":"6","key":"2136_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.12968\/bjon.2018.27.6.328","volume":"27","author":"U Kerin","year":"2018","unstructured":"Kerin U, Wolohan C, Cooke K. Rhabdomyosarcoma: an overview and nursing considerations. Br J Nurs. 2018;27(6):328\u201332.","journal-title":"Br J Nurs"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02136-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-02136-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02136-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:22:46Z","timestamp":1605615766000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02136-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2136"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02136-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"24 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board of National Cheng Kung University Hospital approval to publish this information was obtained (No. A-EC-109-015). The written informed consent was provided by the patient\u2019s parent for participation in this study at National Cheng Kung University Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"490"}}